Active Ingredient History
Pelareorep is a proprietary isolate of the unmodified human reovirus being developed as a systemically administered immuno-oncological viral agent for the treatment of solid tumors and hematological malignancies. Pelareorep is an oncolytic virus, which means that it preferentially lyses cancer cells. Pelareorep also promotes an inflamed tumor phenotype through innate and adaptive immune responses. Preliminary clinical trials indicate that it may have anti-cancer effects across a variety of cancer types when administered alone and in combination with other cancer therapies. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Colorectal Neoplasms (Phase 2)
Fibrosarcoma (Phase 2)
Glioma (Phase 1)
Histiocytoma, Malignant Fibrous (Phase 2)
Leiomyosarcoma (Phase 2)
Lung Neoplasms (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 1)
Osteosarcoma (Phase 2)
Pancreatic Neoplasms (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Skin Neoplasms (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Urinary Bladder Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue